COMMUNIQUÉS West-GlobeNewswire

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
15/04/2025
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today [...]
Chemomab Announces New Medical and Clinical Appointments
15/04/2025
David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the [...]
Lisata Therapeutics Announces Research License with Catalent
15/04/2025
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a [...]
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
15/04/2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer [...]
Extendicare Announces April 2025 Dividend of C$0.042 per Share
15/04/2025
MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the “Common [...]
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
15/04/2025
In combination with atezolizumab or durvalumab Study conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
15/04/2025
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional [...]
Vistin Pharma ASA: Invitation to Q1 2025 conference call
15/04/2025
Oslo, Norway, 15 April 2025 Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the [...]
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
15/04/2025
New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented. ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an [...]
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
15/04/2025
WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers [...]
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
15/04/2025
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of [...]
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares
15/04/2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R PROSPECTUS AND FINAL PROSPECTUS ACCESSIBLE ON SEDAR+ TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ( [...]
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
15/04/2025
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Native Path Native Hydrate Reviews [Urgent Update]: Don’t Buy Until You Read This
15/04/2025
Native Hydrate by Native Path Reviews Woodhaven, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- What if the key to better hydration and muscle recovery wasn’t in sugary sports drinks but in a clean, science-backed formula? [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
15/04/2025
Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc [...]
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
15/04/2025
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, [...]
Best Diabetes Supplement of 2025: Learn How GlucoRedi Sets a New Benchmark in Wellness Industry
15/04/2025
Nampa, April 15, 2025 (GLOBE NEWSWIRE) -- Best Diabetes Supplement of 2025: Learn How GlucoRedi Sets a New Benchmark in Wellness Industry Glucoredi diabetes supplement Content Promoted By Branding EX Solution pvt ltd ( [...]
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
15/04/2025
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi , CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global [...]
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
15/04/2025
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a [...]

Pages